Activities

  • Bringing Bipolar I to Light: Connecting on Diagnosis & Treatment Challenges

    Bipolar I disorder can be challenging to diagnose and treat. To address these challenges, three faculty experts came together during Mental Illness Awareness Week to discuss key issues in bipolar I disorder care. In this 60-minute activity previously aired as a live broadcast, the faculty discuss how you can overcome challenges in diagnosis and treatment adherence. Further, they utilize lecture, discussion, and debate to help you individualize treatment and discuss long-acting injectable (LAI) antipsychotics based on the evidence. 

    Release date: October 10, 2020
    Valid until: October 10, 2021

    Review activity content under the Materials button (below).

  • Exploring Selection + Sequencing: A Multidisciplinary Tumor Board Discussion on Treatment Options for Patients With Advanced HCC

    The number of available systemic treatment options for advanced hepatocellular carcinoma (HCC) has rapidly increased over the last 3 years, providing new hope for patients but also new challenges in treatment selection and sequencing for healthcare professionals (HCPs). To help address these challenges, this 60-minute activity will allow you to “listen in” as a multidisciplinary team of experts discuss a patient case in a style similar to a tumor board meeting. Through this tumor board discussion, the faculty will review the current disease and systemic treatment landscape and provide insight into how they use the most recent data and treatment guideline recommendations to select and sequence treatment for their patients. Best practices for management of symptoms in patients receiving treatment will also be shared.

    Release Date: October 15, 2020
    Valid Until Date: October 15, 2021

    Access course materials, including a Treatment Algorithm, in the Materials section below.

  • Lifting the Burden: Customizing Treatment for Patients With Headache Disorders

    Participate in this on-demand webinar that addresses the challenges of diagnosing and treating primary headache disorders. This interactive program differentiates burden and presentation of a migraine and cluster headache disorder. Faculty experts will share analysis of the latest trial data on acute and preventative therapies to inform your clinical practice. These insights will empower participants to diagnose a headache disorder early and accurately, individualize treatment paradigms, and effectively engage patients on adherence to help ensure long-term disease management.

    Release Date: August 28, 2020
    Valid Until Date: August 28, 2021

  • Migraine Mapped: Charting the neural pathways of headache science with augmented reality

    Powered by Forefront Collaborative, ImmerseRx: Headache is an accredited augmented reality activity that explores the pathophysiology of migraine through an app. This experience will increase your knowledge of what drives migraine and the mechanism of action behind the options for treating it. With ImmerseRx: Headache, you will interact with the human brain at three scene levels: brain, neurovascular, and receptor. Pinch in and zoom out to scale, rotate, raise, or lower the models; walk around the 3D objects to see the animations up close.

    Download the ImmerseRx: Headache augmented reality app now through the Apple Store or Google Play Store.

    Release Date: December 16, 2020
    Valid Until: December 16, 2021

  • PsA+COVID-19: Augmented Reality and Patient Engagement in the Treatment of Psoriatic Arthritis

    COVID-19 has impacted psoriatic arthritis (PsA) patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

    Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use one of the QR codes below or search for it in the Google Play or App Store

    Scan for Google Play Store Scan for Apple Store

    This activity is one of four in this series, PsA+COVID-19: Innovations and Tools for Patient-Centered Psoriatic Arthritis Care.

    For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

    Release Date: June 14, 2021
    Expiration Date: June 14, 2022

  • PSA+COVID-19: Conference Highlights From ACR Convergence 2020

    This 30-minute on-demand broadcast focuses on highlights from the ACR Convergence 2020 conference. You will learn about new evidence regarding psoriatic arthritis (PsA) in the context of COVID-19, presented in a clinical discussion with the prominent rheumatology expert in this clinical area. This broadcast features the latest data synthesized to provide information most relevant to clinical practice. Topics include efficacy and safety of existing and novel targeted therapies for PsA and strategies for minimizing the risk of infections and adverse events for patients with PsA at the time of the COVID-19 pandemic.  

    Release Date: November 24, 2020
    Valid Until: November 24, 2021

  • PSA+COVID-19: Connecting on Patient Care During a Pandemic

    COVID-19 has made providing care to patients with psoriasis and psoriatic arthritis (PsA) more uncertain and complex. This 30-minute online activity is presented by the nationally and internationally recognized rheumatology expert who will review recommendations relevant to treatment of PsA by American College of Rheumatology, National Psoriasis Foundation, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, and European League Against Rheumatism. The presenter also discusses how COVID-19 has impacted rheumatology community views on the use of biologic therapies. This activity features data and clinical scenarios that support and illustrate accurate evaluation of the benefit-to-risk ratio of immunosuppressive therapeutic interventions for PsA. It also covers treatment decisions about initiating, delaying, or stopping, PsA treatment with a conventional, targeted synthetic, or biologic disease-modifying antirheumatic drug (DMARD).   

    Release Date: November 18, 2020
    Valid Until: November 18, 2021

  • PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care

    The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine. 

    To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet before starting the activity. 

    Scan for Google Play Store Scan for Apple Store

    Release Date: March 25, 2021
    Valid Until Date: March 25, 2022